Showing 2301-2310 of 4065 results for "".
Advancing Care: Clinical Innovations on the Horizon
https://reachmd.com/programs/cme/advancing-care-clinical-innovations-on-the-horizon/35881/Learn about LGMD2I/R9—genetics, diagnosis, treatment, clinical trials, and care gaps—in this expert-led, comprehensive educational video series.Stemming the Tide on MASLD/MASH: It Starts on the Frontlines in Endocrinology and Primary Care Clinics
https://reachmd.com/programs/cme/stemming-the-tide-on-masldmash-it-starts-on-the-frontlines-in-endocrinology-and-primary-care-clinics/35568/Join us for a broadcast replay from Global Fatty Liver Day to learn more about cardiometabolic risk factors and improve your care of patients with MASLD/MASH.Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
https://reachmd.com/programs/cme/real-world-igan-a-case-based-approach-to-maximizing-kidney-preservation/26635/Are you implementing the new KDIGO guidelines for IgA nephropathy? Learn how to apply them in clinical practice using a real-world patient case.Beyond RAASi and Approved Therapies: The Unmet Needs in IgAN
https://reachmd.com/programs/cme/beyond-raasi-and-approved-therapies-the-unmet-needs-in-igan/54683/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.The Patient-Clinician Connection in Managing CKD-aP
https://reachmd.com/programs/cme/the-patient-clinician-connection-in-managing-ckd-ap/36302/Review best practices in CKD-aP diagnosis, treatment and management, including the role of multidisciplinary care and shared decision-making to improve quality of life.Molecular Profiling as a Cornerstone of Precision AML Therapy
https://reachmd.com/programs/cme/molecular-profiling-as-a-cornerstone-of-precision-aml-therapy/36178/Explore advances in AML that integrate risk stratification, molecular profiling, and menin-targeted therapies to optimize care and improve outcomes.Recognizing Early Signs of LGMD2I/R9
https://reachmd.com/programs/cme/recognizing-early-signs-of-lgmd2ir9/35878/Learn about LGMD2I/R9—genetics, diagnosis, treatment, clinical trials, and care gaps—in this expert-led, comprehensive educational video series.Emerging Evidence: IgAN Disease-Modifying Agents
https://reachmd.com/programs/cme/emerging-evidence-igan-disease-modifying-agents/54684/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.Establishing Our Foundation of LGMD2I/R9: Unlocking the Genetics
https://reachmd.com/programs/cme/establishing-our-foundation-of-lgmd2ir9-unlocking-the-genetics/35877/Learn about LGMD2I/R9—genetics, diagnosis, treatment, clinical trials, and care gaps—in this expert-led, comprehensive educational video series.Emerging Therapies in IgAN: Who Could Benefit the Most?
https://reachmd.com/programs/cme/emerging-therapies-in-igan-who-could-benefit-the-most/54685/Drs. Lafayette, Risk, Suzuki, and Zhang discuss how APRIL fits into the 4-hit hypothesis of IgAN pathogenesis and review emerging disease-modifying therapies.